Table 3.

Hospitalizations expressed per patient for all patients and for patients actually hospitalized during the trial

	Ivabradine (n = 3241)	Placebo (n = 3264)	P-value
Hospitalizations for worsening heart failure (number of patients)
No hospitalization	2727 (84%)	2592 (79%)
1 hospitalization	325 (10%)	389 (12%)
2 hospitalizations	99 (3%)	155 (5%)
≥3 hospitalizations	90 (3%)	128 (4%)
Hospitalizations for worsening heart failure (number of events)
Total number of hospitalization events	902	1211	0.0002
Number of events per patient
Whole population	0.3	0.4
Patients with ≥1 hospitalization	1.8	1.8
Hospitalizations for any cause (number of patients)
No hospitalization	2010 (62%)	1908 (58%)
1 hospitalization	613 (19%)	646 (20%)
2 hospitalizations	297 (9%)	313 (10%)
≥3 hospitalizations	321 (10%)	397 (12%)
Hospitalizations for any cause (number of events)
Total number of hospitalization events	2661	3110	0.001
Number of events per patient
Whole population	0.8	1.0
Patients with ≥1 hospitalization	2.2	2.3

P-values comparing patients in the ivabradine and placebo groups (Poisson's regression model).